Previous 10 | Next 10 |
2024-01-16 12:55:23 ET Gainers: Phunware ( PHUN ) +258% . DatChat ( DATS ) +61% . SEALSQ Corp ( LAES ) +40% . HomeStreet ( HMST ) +39% . Altisource Asset Management Corp ( AAMC ) +37% . Jin Medical International Ltd ( ZJYL ...
2024-01-16 07:40:49 ET More on Allakos Seeking Alpha’s Quant Rating on Allakos Historical earnings data for Allakos Financial information for Allakos For further details see: Allakos crashes on restructuring plans
Existing cash to fund planned ongoing operations into mid-2026 AK006 is being tested in a comprehensive Phase 1 clinical program, including: ongoing single and multiple ascending dose trial in healthy volunteers a randomized, double-blind, placebo-controlled trial in patients with CSU...
– Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and webcast today at 8:00 am E.T. – SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE...
2023-12-18 06:15:01 ET William Blair analyst issues OUTPERFORM recommendation for ALLK on December 18, 2023 06:04AM ET. ALLK was trading at $3 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recom...
2023-11-14 01:49:52 ET More on Allakos Scratching The Surface: Allakos' Novel Take On Urticaria Allokos stock jumps 16% as JMP starts coverage at market outperform Seeking Alpha’s Quant Rating on Allakos Historical earnings data for Allakos Fin...
2023-11-13 17:16:01 ET More on Allakos Scratching The Surface: Allakos' Novel Take On Urticaria Seeking Alpha’s Quant Rating on Allakos For further details see: Allakos files to sell up to $250M worth of its common stock
SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results fo...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
2023-11-09 07:30:35 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s time to start the day with a breakdown of the biggest pre-market stock movers worth keeping tabs on for Thursday! Earnings reports continue to be a major catalyst for stocks thi...
News, Short Squeeze, Breakout and More Instantly...
Allakos Inc. Company Name:
ALLK Stock Symbol:
NASDAQ Market:
SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results f...
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...